CoChat

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

Weiner, Louis M., Belldegrun, Arie S., Crawford, Jeffrey, Tolcher, Anthony W., Lockbaum, Pamela, Arends, Rosalin H., Navale, Lynn, Amado, Rafael G., Schwab, Gisela, Figlin, Robert A. · 2008 · Clinical Cancer Research
Cited by 125

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose: This phase 1 study evaluated the safety, pharmacokinetics, and activity of panitumumab, a fully human, IgG2 monoclonal antibody that targets the epidermal growth factor receptor in patients with previously treated epidermal growth factor receptor–expressing advanced solid tumors. Experimental Design: Sequential cohorts were enrolled to receive four i.v. infusions of panitumumab monotherapy at various doses and schedules. Safety was continuously monitored. Serum samples for pharmacokinetic, immunogenicity, and chemistry assessments were drawn at preset intervals. Tumor response was assessed at week 8. Results: Ninety-six patients received panitumumab. Median (range) age was 61 years (32-79 years), and 72 (75%) patients were male. Tumor types were 41% colorectal cancer, 22% prostate, 16% renal, 15% non–small cell lung, 3% pancreatic, 3% esophageal/gastroesophageal, and 1% anal. The overall incidence of grade 3 or 4 adverse events was 32% and 7%, respectively. The incidence of skin-related toxicities was dose dependent. No maximum tolerated dose was reached. No human anti-panitumumab antibodies were detected. No investigator-determined panitumumab infusion-related reactions were reported. Serum panitumumab concentrations were similar in the 2.5 mg/kg weekly, 6.0 mg/kg every 2 weeks, and 9.0 mg/kg every 3 weeks dose cohorts. Five of 39 patients (13%) with colorectal cancer had a confirmed partial response, and 9 of 39 patients (23%) with colorectal cancer had stable disease. Conclusions: Panitumumab was well tolerated with comparable exposure and safety profiles for the weekly, every 2 weeks, and every 3 weeks administration schedules. Rash and dry skin occurred more frequently in the dose cohorts receiving ≥2.5 mg/kg weekly dose. Panitumumab has single-agent antitumor activity, most notably in patients with advanced colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-1509

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 125

Metadata

Authors
Weiner, L. M., Belldegrun, A. S., Crawford, J., Tolcher, A. W., Lockbaum, P., Arends, R. H., Navale, L., Amado, R. G., Schwab, G., & Figlin, R. A.
Venue
Clinical Cancer Research
Published
2008-01-15
Volume
14
Issue
2
Pages
502-508
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2103196676
Cited by
125
References
6
FWCI
6.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1509
The paper
Weiner, L. M., Belldegrun, A. S., Crawford, J., Tolcher, A. W., Lockbaum, P., Arends, R. H., Navale, L., Amado, R. G., Schwab, G., & Figlin, R. A. (2008). Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1509

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.